Relx (LON:REL)‘s stock had its “buy” rating reaffirmed by stock analysts at Liberum Capital in a research report issued to clients and investors on Friday.
Several other equities research analysts have also recently issued reports on REL. UBS Group reiterated a “sell” rating on shares of Relx in a report on Monday, September 3rd. Barclays upgraded Relx to an “overweight” rating and lifted their price objective for the stock from GBX 1,615 ($21.10) to GBX 1,740 ($22.74) in a report on Monday, September 24th. Berenberg Bank reiterated a “buy” rating and issued a GBX 1,800 ($23.52) price objective on shares of Relx in a report on Monday, October 8th. Deutsche Bank reiterated a “buy” rating on shares of Relx in a report on Thursday, November 1st. Finally, Credit Suisse Group lifted their price objective on Relx from GBX 1,840 ($24.04) to GBX 1,940 ($25.35) and gave the stock an “outperform” rating in a report on Thursday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. Relx presently has an average rating of “Buy” and a consensus target price of GBX 1,780.77 ($23.27).
REL stock opened at GBX 1,632.50 ($21.33) on Friday. Relx has a 12-month low of GBX 1,399 ($18.28) and a 12-month high of GBX 1,784 ($23.31).
RELX PLC provides information and analytics for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals.
Featured Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.